For decades, mainstream medicine has portrayed acetylcholine as the “learning neurotransmitter” and serotonin as the “happy hormone.” Drugs that raise acetylcholine (Alzheimer’s treatments like Aricept) and drugs that raise serotonin (SSRIs for depression and OCD) have been prescribed to millions, despite marginal efficacy and significant side effects. Ray has written extensively about the dark side of both molecules: acetylcholine is a stress signal linked to estrogen dominance and neurological dysfunction, while serotonin is a pro-fibrotic, anti-metabolic agent.
The study below, published in Nature Communications, now reveals that acetylcholine directly controls serotonin release in the dorsal striatum — meaning raising acetylcholine inevitably raises serotonin, compounding the damage. The researchers identified specialized cells called cholinergic interneurons (CINs) that act like “conductors” in an orchestra, and they found that this coupling is region-specific (present in dorsal striatum but not ventral striatum). In OCD models, this system runs in “overdrive,” and the nAChR-dependent component of serotonin release is selectively amplified.
As the study below demonstrates, researchers from Hebrew University and Stony Brook University used optogenetics to show that acetylcholine can directly trigger serotonin release in the dorsal striatum. Cholinergic interneurons (CINs) — which were already known to control dopamine — can also directly trigger serotonin release via nicotinic acetylcholine receptors (nAChRs) on serotonergic axons. In pre-clinical models of OCD (Sapap3-/- mice), acetylcholine levels are hyperactive, driving a massive surge of serotonin release. The study also found that this acetylcholine–serotonin coupling is not detectable in the ventral striatum, despite its denser serotonergic innervation — meaning the brain has region-specific wiring that allows one system to “take the wheel” only in certain areas.
This finding completely upends the mainstream narrative. Consider the implications:
-
Alzheimer’s disease: The standard of care has been acetylcholinesterase inhibitors (Aricept, etc.) that raise acetylcholine. These drugs have universally failed to cure or even meaningfully ameliorate Alzheimer’s. Now we know why: raising acetylcholine triggers serotonin release, and high serotonin is known to negatively impact brain health (inflammation, fibrosis, mitochondrial dysfunction). The failure of these drugs is not mysterious — they were targeting the wrong direction.
-
OCD: Mainstream medicine treats OCD with SSRIs — drugs that raise serotonin. Yet this study shows that in OCD models, acetylcholine is already elevated, driving excessive serotonin release. As the researchers note in the Q&A section: “It’s like blaming a loud orchestra on the violins (serotonin) when the conductor (acetylcholine) is actually the one waving the baton too fast.” SSRIs are “managing the symptoms” of the chemical surge, but the true source is the overactive acetylcholine system. This explains why SSRIs benefit only a fraction of OCD patients and cure even fewer. The truth is exactly backwards: OCD is a state of excess acetylcholine and excess serotonin, and the treatment should aim to lower both, not raise them.
-
The acetylcholine-serotonin axis: I have written previously about the direct link between acetylcholine and estrogen signaling. Estrogen upregulates cholinergic activity, which then drives serotonin release. This is why women with estrogen dominance often present with anxiety, OCD-like symptoms, and depression — all of which are then “treated” with SSRIs that make the underlying problem worse.
The study did not provide animal doses or human-equivalent doses, as it was a mechanistic optogenetic study. However, the therapeutic implications are clear: blocking the acetylcholine→serotonin interaction (via anticholinergic agents or nicotinic receptor antagonists) is a more logical approach than raising serotonin with SSRIs or raising acetylcholine with Alzheimer’s drugs. The researchers explicitly state that “this research opens the door for a new generation of treatments that target the ‘conductor’ cells instead.”
https://www.nature.com/articles/s41467-026-70359-6
…Researchers have discovered a master coordination strategy in the brain… In a new study, scientists found that in the striatum—the brain’s movement and learning hub—acetylcholine doesn’t just work alongside serotonin; it can actually ‘take the wheel. ‘”
…Specialized cells called cholinergic interneurons act like conductors, directly triggering the release of serotonin. This powerful link means that when acetylcholine goes into overdrive, it drags serotonin levels up with it, potentially explaining the pathological ‘loop’ seen in conditions like Obsessive-Compulsive Disorder (OCD).
…When the researchers examined brain states linked to Obsessive-Compulsive–like behaviors, they found the system running in overdrive. The cholinergic cells were overactive, driving a surge of serotonin release.
…’It’s like blaming a loud orchestra on the violins (serotonin) when the conductor (acetylcholine) is actually the one waving the baton too fast. This study shows that the serotonin surge in OCD might be a reaction to an overactive acetylcholine system. ‘
…’Current drugs (like SSRIs) help by managing the ‘symptoms’ of the chemical surge. However, this research opens the door for a new generation of treatments that target the ‘conductor’ cells instead. If we can calm the acetylcholine ‘conductors,’ we might be able to prevent the serotonin imbalance from happening in the first place. ‘
…In Sapap3-/- mice, a model of obsessive-compulsive disorder (OCD)-like behavior, this mechanism is exaggerated due to a hypercholinergic state, selectively amplifying the nAChR-dependent component of monoamine release. These findings demonstrate a regionally confined form of acetylcholine–5-HT crosstalk in the striatum and identify CINs as regulators of 5-HT dynamics in both healthy and pathological states.
